Question explored with the scientific record
Are statins bad for you to take
The short version: statins reduce heart attacks and deaths in people who already have heart disease, but the benefit is smaller for healthy people and comes with real side effects.
The evidence for statins in people who already have heart disease is solid. A meta-analysis of 14 randomized trials found statins cut the risk of dying from any cause by about 24% [5]. In people with peripheral artery disease, statins lowered all-cause death by about 40% [3]. For patients getting heart bypass surgery, taking a statin within 24 hours before surgery dropped 30-day death from 3.8% to 1.7% [6]. These are hard clinical outcomes from randomized trials and large observational studies.
For healthy people without heart disease, the picture is murkier. The benefit is smaller and the trade-offs matter more. Statins raise the risk of new diabetes by about 9-13% [20, 27]. In older adults on Medicare, statin use was linked to a 26% higher chance of developing diabetes [27]. Muscle pain affects 1.5-5% of people in trials, but in real-world practice about 10% report muscle symptoms [29, 32]. The risk of serious muscle damage is low but real: the FDA database recorded 3,339 cases of rhabdomyolysis from 1990-2002 [30].
The key question is who you are. For someone with established heart disease, the benefit clearly outweighs the risks. For a healthy person with no heart disease, the benefit is modest and the diabetes risk is a real concern. The evidence does not support putting everyone over a certain age on a statin as if it were a vitamin.
| Group | All-cause death reduction | New diabetes risk | Muscle symptoms |
|---|---|---|---|
| People with heart disease | ~24% lower [5] | 9-13% higher [20] | 1.5-5% in trials [32] |
| Healthy people (primary prevention) | Smaller, varies by age [11] | 26% higher in older adults [27] | ~10% in practice [29] |
My call: statins are clearly beneficial for people with established heart disease, but for healthy people the benefit is smaller and the diabetes risk is real. Confidence: high for secondary prevention, moderate for primary prevention.
Sources used 48
-
Continuation of Statin Treatment and All-Cause Mortality
This population-based cohort study evaluates the impact of statin therapy on all-cause mortality among patients with and without coronary heart disease, finding that better continuity of treatment significantly reduces mortality risk.
DOI: 10.1001/archinternmed.2008.552 -
U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
Non-HDL-C demonstrated a U-shaped relationship with all-cause and cardiovascular mortality in 12,574 US men without statin therapy, with lowest mortality risk at approximately 142-144 mg/dl.
DOI: 10.3389/fcvm.2022.903481 -
Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis
A systematic review and meta-analysis showing that statin therapy reduces all-cause mortality and stroke in patients with lower limb peripheral arterial disease, although evidence for cardiovascular mortality and myocardial infarction is less clear and overall study quality is l…
DOI: 10.1016/j.vph.2014.09.001 -
Relationships of Statin Therapy and Hyperlipidemia With the Incidence, Rupture, Postrepair Mortality, and All-Cause Mortality of Abdominal Aortic Aneurysm and Cerebral Aneurysm: A Meta-analysis and Systematic Review
Statin therapy was associated with reduced risks of abdominal aortic aneurysm rupture, postrepair mortality, all-cause mortality, and adverse events, and hyperlipidemia was associated with lower risk of cerebral aneurysm rupture, without increasing aneurysm incidence.
DOI: 10.1097/fjc.0000000000000653 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery
This study investigates the impact of the timing and dosage of preoperative statin therapy on 30-day all-cause mortality in patients undergoing coronary artery bypass graft surgery, finding that administration within 24 hours and doses greater than 20 mg significantly reduce mor…
DOI: 10.1016/j.athoracsur.2016.12.043 -
Preoperative statin therapy is associated with reduced 30-day postoperative all-cause mortality in patients undergoing coronary artery bypass surgery: A meta-analysis of large size observational studies
A meta-analysis of large-size observational studies (n=30,955) indicates that preoperative statin therapy is associated with a significant reduction in 30-day postoperative all-cause mortality after isolated coronary artery bypass grafting (CABG), with consistent findings across…
DOI: 10.1016/j.ijcard.2014.11.216 -
Meta-analysis of statin therapy in maintenance dialysis patients
This meta-analysis investigates the effects of statin therapy on major clinical outcomes in maintenance dialysis patients, revealing significant improvements in dyslipidemia and inflammatory markers but no impact on cardiovascular or all-cause mortality.
DOI: 10.3109/0886022x.2015.1061871 -
Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis
A meta-analysis of 12 cohort studies involving 162,252 people living with HIV found statin use associated with reduced all-cause mortality and cancer risk, but no significant association with cardiovascular events.
DOI: 10.3389/fmed.2021.769740 -
Impact of Statin Use After Heart Transplantation
This meta-analysis evaluates the impact of statin therapy on heart transplant recipients, demonstrating significant reductions in all-cause mortality, hemodynamically significant rejection, coronary vasculopathy, and terminal cancer risk.
DOI: 10.1161/CIRCHEARTFAILURE.116.003265 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy
A comprehensive meta-analysis of 29 randomized trials (266,148 patients) shows that baseline body mass index (BMI) modulates the cardiovascular benefit of intensive LDL-C lowering therapy, with the greatest reductions in cardiovascular and all-cause mortality observed in individ…
DOI: 10.1016/j.amjcard.2019.12.006 -
Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
This study investigates the prevalence of healthy lifestyle factors among adults at high risk for atherosclerotic cardiovascular disease (ASCVD) who are candidates for statin therapy, finding that increased adherence to healthy lifestyles is associated with lower risks of incide…
DOI: 10.1016/j.ijcard.2016.01.001 -
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
This systematic review and meta-analysis evaluates the efficacy and safety of statin and ezetimibe combination therapy in patients with chronic kidney disease, finding significant improvements in lipid profiles and reductions in all-cause mortality and major adverse cardiovascul…
DOI: 10.1002/cpt.1859 -
Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study
A large Swedish cross-sectional register study in primary care shows many patients with coronary heart disease do not meet LDL-C targets or use adequate statin therapy, and modelling suggests that improved adherence and intensified statin regimens could substantially reduce 5-ye…
DOI: 10.1136/bmjopen-2020-036920 -
Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study
Incident diabetes during statin therapy does not worsen cardiovascular outcomes and does not diminish the cardioprotective benefits of statins, based on two nationwide propensity-matched Korean cohorts.
DOI: 10.1186/s12933-025-03003-0 -
Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study
Population-based, nationwide cohort analyses show that baseline cholesterol levels are differentially associated with dementia risk depending on diabetes status and statin use, with an inverted J-shaped pattern in statin non-users and a positive LDL-C association among statin us…
DOI: 10.1038/s41598-022-24153-1 -
Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention
This review examines the association between statin therapy and the risk of new-onset diabetes, highlighting that while statins may increase diabetes risk, the cardiovascular benefits significantly outweigh this risk, particularly in individuals with pre-existing diabetes risk f…
DOI: 10.1007/s11886-024-02141-3 -
Therapy and clinical trials
This paper discusses the implications of the ACC/AHA Blood Cholesterol Guidelines on statin therapy, highlighting the increased risk of diabetes associated with higher potency statins while emphasizing the importance of dietary modifications in managing cholesterol levels.
DOI: 10.1097/mol.0000000000000116 -
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
This meta-analysis investigates the relationship between statin therapy and the risk of developing diabetes, finding a slight increase in diabetes risk associated with statin use, particularly in older populations, while emphasizing that the cardiovascular benefits of statins ou…
DOI: 10.1016/s0140-6736(09)61965-6 -
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
A comprehensive review and practical guidance for clinicians on the diabetes risk associated with statin therapy, evaluating the evidence that statins modestly increase type 2 diabetes risk—especially at high doses—and outlining risk stratification, monitoring, and lifestyle mea…
DOI: 10.1016/j.atherosclerosissup.2014.04.001 -
The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin
This study investigates the prevalence and factors associated with aspirin resistance among Jordanian patients, finding that 18.7% of patients are resistant, with significant associations to female gender and diabetes, while statin use improves aspirin response.
DOI: 10.1080/ac.67.4.2170686 -
Association between Statin Use and Sensorineural Hearing Loss in Type 2 Diabetic Patients: A Hospital-Based Study
This study investigates the association between statin use and the risk of sensorineural hearing loss (SNHL) or tinnitus in type 2 diabetic patients, finding that statin use significantly reduces the risk of these conditions.
DOI: 10.3390/ph14111076 -
Relation of Exercise Capacity to Risk of Development of Diabetes in Patients on Statin Therapy (the Henry Ford Exercise Testing Project)
This study investigates the relationship between exercise capacity and the risk of developing diabetes in patients undergoing statin therapy, finding that higher exercise capacity is associated with a lower risk of incident diabetes regardless of statin use.
DOI: 10.1016/j.amjcard.2017.05.048 -
Statins for primary prevention in physically active individuals: Do the risks outweigh the benefits?
This study investigates the association between statin use and cardiovascular outcomes as well as adverse events, particularly diabetes, in physically active military personnel, finding that statin use is linked to increased diabetes risk without significant cardiovascular benef…
DOI: 10.1016/j.jsams.2016.12.075 -
Adverse effects of statin therapy: real evidence
Statins confer clear cardiovascular benefits with generally favorable tolerability; adverse events are typically mild and dose-dependent, while concerns about diabetes, liver function, and cognition are not strongly supported by evidence, and nocebo/drucebo effects contribute to…
DOI: 10.26442/22217185.2019.1.190264 -
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
This retrospective cohort study of 89,390 Medicare Advantage patients aged ≥65 years found that statin use was associated with new onset type 2 diabetes, with a matched propensity score analysis yielding an odds ratio of 1.26 (95% CI: 1.12–1.41).
DOI: 10.1002/dmrr.3310 -
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
This study investigates the independent associations of metformin, statins, and aspirin with overall mortality among colorectal cancer patients with diabetes, revealing that while statin use is associated with lower mortality, metformin and aspirin do not show such associations …
DOI: 10.1038/bjc.2015.259 -
Statin intolerance in a referral lipid clinic
This study investigates the prevalence and types of statin-associated adverse events in a cohort of 642 patients evaluated at a referral lipid clinic, highlighting the predominance of musculoskeletal symptoms and the challenges in managing statin intolerance.
DOI: 10.1016/j.jacl.2016.03.004 -
Statin-Associated Myopathy
Statins are associated with skeletal muscle complaints including myositis, rhabdomyolysis, myalgia, weakness, and cramps; the FDA MEDWATCH database lists 3339 cases of statin-associated rhabdomyolysis from 1990 to 2002, with cerivastatin most commonly implicated, and risk is exa…
DOI: 10.1001/jama.289.13.1681 -
Adverse effects of statin therapy and their treatment
A narrative review summarizing the adverse effects of statin therapy (hepatic dysfunction, myopathy, and diabetes risk) and their management, comparing major international guidelines and offering practical recommendations.
DOI: 10.36011/cpp.2022.4.e4 -
Narrative Review: Statin-Related Myopathy
This narrative review synthesizes current knowledge on statin-related myopathy, detailing definitions, mechanisms, epidemiology, clinical features, risk factors, management strategies, and emerging pharmacogenetic and adjunctive treatment data.
DOI: 10.7326/0003-4819-150-12-200906160-00009 -
Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database
This study characterizes statin-associated muscle-related adverse events in Thailand using the national pharmacovigilance database, revealing significant patterns in patient demographics, drug interactions, and outcomes.
DOI: 10.1007/s40264-013-0055-5 -
Statin Safety: An Assessment Using an Administrative Claims Database
This study assesses the safety of statins and other lipid-lowering therapies by analyzing hospitalization rates for adverse events using a large administrative claims database covering over 9 million patients in the United States.
DOI: 10.1016/j.amjcard.2005.12.011 -
Statin-Associated Bilateral Foot Myopathy
A 44-year-old male with cardiovascular disease developed bilateral foot pain, weakness, and soreness after starting atorvastatin 20 mg daily, which resolved upon discontinuation and recurred years later with rosuvastatin 20 mg daily, leading to a definite Naranjo score for stati…
DOI: 10.1177/0897190019857851 -
Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients
An observational study of long-term clevudine monotherapy in 110 treatment-naïve chronic hepatitis B patients showing strong initial HBV DNA suppression and biochemical response, followed by virological breakthrough with rtM204I-related resistance in many cases, and a notable in…
DOI: 10.5812/hepatmon.6056 -
Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia
A multicenter, randomized, double-blind trial in children with heterozygous familial hypercholesterolemia shows that simvastatin (10–40 mg daily) markedly lowers LDL-C with favorable lipid changes and no major growth or pubertal adverse effects over 48 weeks, though long-term ou…
DOI: 10.1161/01.cir.0000035247.42888.82 -
Thiazolidinedione exposure duration defines MI risk
This study evaluates the safety of rosuvastatin compared to other statins, finding no significant increase in adverse events among rosuvastatin users based on two large retrospective database analyses.
DOI: 10.2165/00128413-200816650-00042 -
Optimizing Statin Therapy in Older Adults: A Systematic Review of Dosing, Titration, and Combination Strategies
This systematic review synthesizes dosing, titration, and ezetimibe-addition strategies for statin therapy in older adults, finding that individualized dosing and combination therapy can improve lipid targets and potentially outcomes, with adherence and safety considerations bei…
DOI: 10.1007/s11357-025-01772-w -
Effects of Statin Use on Muscle Strength, Cognition, and Depressive Symptoms in Older Adults
Among older veterans, long-term statin use did not worsen proximal muscle strength, cognition, or depressive symptoms over about one year, with only a possible depressive signal in highly comorbid subgroups.
DOI: 10.1111/j.1532-5415.2007.01071.x -
National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013
This study analyzes trends in statin use and associated expenditures among US adults aged 40 and older from 2002 to 2013, revealing significant increases in usage but persistent disparities in high-risk populations.
DOI: 10.1001/jamacardio.2016.4700 -
From Here to JUPITER
Using NHANES 1999-2004 data, the authors estimated that 19.2% of US men ≥50 and women ≥60 (11.1 million) would become newly eligible for statin therapy under JUPITER criteria, bringing the proportion with any indication to nearly 80%.
DOI: 10.1161/circoutcomes.108.832592 -
N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes
This comprehensive review synthesizes recent evidence (from 2020 onward) on omega-3 polyunsaturated fatty acids (EPA and DHA) and cardiovascular disease, detailing mechanisms, cohort associations, and randomized trials with overall findings of dose- and context-dependent benefit…
DOI: 10.1007/s11883-025-01363-2 -
Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events
A viewpoint summarizing niacin–statin surrogate imaging trials in the AIM-HIGH era, highlighting that imaging improvements from niacin do not clearly translate into reduced cardiovascular events and that the ultimate clinical benefit remains uncertain pending large outcome trial…
DOI: 10.1016/j.jacc.2012.01.045 -
The effect of a multi-component behavior change technique intervention on medication adherence among individuals on primary prevention statin therapy: a dose-finding protocol
Minimum-dose determination of a multi-component behavior change technique to increase statin adherence among adults on primary prevention statin therapy using a TiTE-CRM adaptive dose-finding design.
DOI: 10.1186/s13063-023-07549-w -
Evaluating the Potential Statin-Drug Interactions among Older Patients with Chronic Diseases in Sana’a City, Yemen
Prevalence and severity of potential statin-drug interactions among older adults (55+) on statin therapy in Sana'a City, Yemen, were evaluated, revealing 27% had at least one statin-drug interaction (predominantly category C), with atorvastatin implicated most often and a strong…
DOI: 10.23880/apct-16000209 -
Compliance in primary prevention with statins and associations with cardiovascular risk and death in a low-risk diabetes population
In a Danish nationwide cohort of 59,985 adults with newly diagnosed diabetes, statin use in primary prevention with high adherence reduced the 5-year risk of cardiovascular events or death, with greater benefit at higher adherence and older ages.
DOI: 10.1093/ehjci/ehaa946.3068 -
Relationships between Medication Adherence and Cardiovascular Disease Risk Factor Control in Elderly Patients with Diabetes
In elderly adults with diabetes within Kaiser Permanente, adherence to ACEI/ARB and statins (per Medicare Star targets) showed little link between ACEI/ARB adherence and blood pressure control in the very elderly or those with many comorbidities, while targeted statin adherence …
DOI: 10.1002/phar.1994